Anti-SIGLEC11 (C-term) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution

Not available outside of the UK & Ireland.

General description

SIGLECs are members of the immunoglobulin superfamily that are expressed on the cell surface. Most SIGLECs have one or more cytoplasmic immune receptor tyrosine-based inhibitory motifs (ITIM). SIGLECs are typically expressed on cells of the innate immune system, with the exception of the B-cell expressed SIGLEC6. Sequence analysis predicted that the 697-amino acid SIGLEC10 protein contains a signal peptide, an N-terminal V-set Ig-like domain and four C2-set Ig-like domains, five potential N-linked glycosylation sites, a transmembrane region, and a 126-residue cytoplasmic tail with 3 putative ITIMs. Northern blot analysis detected a major 3.0-kb SIGLEC10 transcript, with highest levels in spleen, lymph node, blood leukocytes, and appendix. Little or no expression was observed in pancreas, thyroid, and testis. Flow cytometric analysis demonstrated eosinophil-specific expression of SIGLEC10, but at a lower level than that of SIGLEC8. Expression was also detected on monocytes and a CD16-positive/CD56-negative natural killer-like lymphocyte population. After sialidase treatment, which is necessary for unmasking the sialic acid-binding site on SIGLECs interacting with cell surface sialic acids, cells expressing SIGLEC10 bound to red blood cells. Immunoprecipitation analysis indicated expression of a 100- to 120-kD monomeric protein, higher than the predicted molecular mass, suggesting that SIGLEC10 is glycosylated. This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human SIGLEC11.

Immunogen

SIGLEC11 (AAK72907, 624-660)This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human SIGLEC11.

Physical form

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.